Cyprus vs Chinese Taipei: Protecting minority investors: Strength of minority investor
Cyprus
38 DB15-20 methodology
in 2019
Chinese Taipei
38 DB15-20 methodology
in 2019
Cyprus rank
21st
Chinese Taipei rank
21st
Protecting minority investors: Strength of minority investor over time
- Cyprus
- Chinese Taipei
How they compare
Cyprus currently reports 38 DB15-20 methodology against 38 DB15-20 methodology in Chinese Taipei, a difference of 0 DB15-20 methodology.
Across all 7 years both countries report, Chinese Taipei has been ahead every year.
Cyprus ranks 21st and Chinese Taipei ranks 21st of 191 countries.
Chinese Taipei has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher protecting minority investors: strength of minority investor, Cyprus or Chinese Taipei?
- Cyprus, at 38 DB15-20 methodology against 38 DB15-20 methodology in Chinese Taipei as of 2019.
- What is the difference in protecting minority investors: strength of minority investor between Cyprus and Chinese Taipei?
- 0 DB15-20 methodology, with Cyprus ahead.
- How many years of comparable data are there for Cyprus and Chinese Taipei?
- 7 years are reported by both, from 2013 to 2019.
- How do Cyprus and Chinese Taipei rank globally for protecting minority investors: strength of minority investor?
- Cyprus ranks 21st and Chinese Taipei ranks 21st of 191 countries.
- Where does this data come from?
- The World Bank, published as Protecting minority investors: Strength of minority investor protection index (0-50) (DB15-20 methodology). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The strength of minority investor protection index is the sum of the extent of disclosure index, extent of director liability index, ease of shareholder suits index, extent of shareholder rights index, extent of ownership and control index and extent of corporate transparency index. The index is computed based on the methodology in the DB15-20 studies.